Endo International | ENDP - Le Bénéfice D'Exploitation



Le Bénéfice D'Exploitation Changement Date
AbbVie USD 6.72B 1.99B 2026-06
Amarin USD -2.26M 564K 2025-12
ANI Pharmaceuticals USD 39.84M 1.13M 2026-06
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Coherus Biosciences USD -39.08M 3.65M 2025-12
Eli Lilly USD 12.46B 2.68B 2026-06
Heron Therapeutics USD 38K 3.83M 2025-12
Hikma Pharmaceutical USD 348M 161M 2025-12
Ligand Pharmaceuticals USD 56.62M 3.7M 2026-06
Merck USD 840M 2.72B 2026-06
Novartis USD 4.75B 515M 2026-06
Pacira USD 9.96M 5.33M 2026-06
Perrigo USD 23.5M 10.1M 2026-06
Pfizer USD 667M 4.32B 2026-06
Phibro Animal Health USD 54.99M 2.36M 2025-12
Supernus Pharmaceuticals USD -21.04M 14.21M 2026-06
Takeda JPY 201.42B 215.04B 2026-06
Teva Pharmaceutical Industries USD 235M 523M 2026-06
Xeris Pharmaceuticals USD 7.92M 8.86M 2026-03
Zoetis USD 1.12B 256M 2026-06